OpGen > Investor Relations > Overview


Corporate Profile

OpGen, Inc. is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant bacterial infections. The company’s products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. The company’s lead product is the Acuitas® MDRO Gene Test. Products in development include the Acuitas Lighthouse™ MDRO Management System and the Acuitas Resistome Test. In addition, the company has more than 10 years of experience mapping microbial, plant and human genomes.

Upcoming Events

There are currently no events scheduled.

More Events

OPGN (Common Stock)
Exchange :NASDAQ CM (US Dollar)
Financial Status IndicatorC
Price :$1.10
Change : Stock is Down 0.06 (5.17%)
Volume :8,526
Data as of 12/07/16 4:00 p.m. ET
Minimum 20 minute delay
Data Provided by Thomson Reuters